Literature DB >> 7684822

Risk factors for hepatocellular carcinoma among patients with chronic liver disease.

H Tsukuma1, T Hiyama, S Tanaka, M Nakao, T Yabuuchi, T Kitamura, K Nakanishi, I Fujimoto, A Inoue, H Yamazaki.   

Abstract

BACKGROUND AND METHODS: To detect potentially curable cases of hepatocellular carcinoma, outpatients with chronic hepatitis or compensated liver cirrhosis who were seen at the Center for Adult Diseases (Osaka, Japan) were examined periodically by means of ultrasonography and measurement of serum alpha-fetoprotein. Risk factors for hepatocellular carcinoma were identified with a Cox proportional-hazards model.
RESULTS: A total of 917 patients, 40 to 69 years old, were registered from May 1987 to March 1991. By the end of September 1991, liver cancer had developed in 54. The three-year cumulative risk of liver cancer was 12.5 percent for 240 patients with liver cirrhosis at enrollment and 3.8 percent for 677 patients with chronic hepatitis. Cox regression analysis showed that the risk of liver cancer was increased almost sevenfold in patients with hepatitis B surface antigen (rate ratio, 6.92; 95 percent confidence interval, 2.92 to 16.39) and fourfold in patients with hepatitis C antibody (rate ratio, 4.09; 95 percent confidence interval, 1.30 to 12.85). A high alpha-fetoprotein value at enrollment was also a risk marker for liver cancer.
CONCLUSIONS: Patients with hepatitis C virus infection have a greatly increased risk of liver cancer. Further studies are required to clarify the roles of other risk factors, including drinking and smoking habits.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7684822     DOI: 10.1056/NEJM199306243282501

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  234 in total

1.  Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis.

Authors:  A Gramenzi; P Andreone; S Fiorino; C Cammà; M Giunta; D Magalotti; C Cursaro; C Calabrese; V Arienti; C Rossi; G Di Febo; M Zoli; A Craxì; G Gasbarrini; M Bernardi
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

2.  Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy.

Authors:  Nikolaus Kohles; Dorothea Nagel; Dietrich Jüngst; Jürgen Durner; Petra Stieber; Stefan Holdenrieder
Journal:  Tumour Biol       Date:  2011-09-20

3.  Effects of gadoxetic acid on liver elasticity measurement by using magnetic resonance elastography.

Authors:  Utaroh Motosugi; Tomoaki Ichikawa; Hironobu Sou; Katsuhiro Sano; Ali Muhi; Richard L Ehman; Tsutomu Araki
Journal:  Magn Reson Imaging       Date:  2011-09-19       Impact factor: 2.546

4.  Management of chronic hepatitis C and prevention of hepatocellular carcinoma.

Authors:  Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

5.  Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults.

Authors:  S D Ryder
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

6.  In vivo assessment of angioarchitecture and microcirculation in experimental liver cancer: a new model in rats.

Authors:  S M Maksan; H Paulo; E Ryschich; C Kuntz; M M Gebhard; E Klar; J Schmidt
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

7.  Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.

Authors:  Jagpreet Chhatwal; Shannon A Ferrante; Cliff Brass; Antoine C El Khoury; Margaret Burroughs; Bruce Bacon; Rafael Esteban-Mur; Elamin H Elbasha
Journal:  Value Health       Date:  2013 Sep-Oct       Impact factor: 5.725

8.  Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI.

Authors:  Scott M Thompson; Ishan Garg; Eric C Ehman; Shannon P Sheedy; Candice A Bookwalter; Rickey E Carter; Lewis R Roberts; Sudhakar K Venkatesh
Journal:  Br J Radiol       Date:  2018-08-29       Impact factor: 3.039

9.  Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma.

Authors:  Soocheol Jeong; Hiroshi Aikata; Yoshio Katamura; Takahiro Azakami; Tomokazu Kawaoka; Hiromi Saneto; Kiminori Uka; Nami Mori; Shintaro Takaki; Hideaki Kodama; Koji Waki; Michio Imamura; Hiroo Shirakawa; Yoshiiku Kawakami; Shoichi Takahashi; Kazuaki Chayama
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

10.  Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma.

Authors:  Soo Cheol Jeong; Hiroshi Aikata; Yoshio Katamura; Takahiro Azakami; Tomokazu Kawaoka; Hiromi Saneto; Kiminori Uka; Nami Mori; Shintaro Takaki; Hideaki Kodama; Koji Waki; Michio Imamura; Hiroo Shirakawa; Yoshiiku Kawakami; Shoichi Takahashi; Kazuaki Chayama
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.